Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual MeetingGlobeNewsWire • 11/04/21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid TumorsGlobeNewsWire • 10/27/21
Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia PatientsGlobeNewsWire • 08/24/21
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/13/21
Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021GlobeNewsWire • 08/06/21
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/14/21
Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021GlobeNewsWire • 05/07/21
Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia StudyBenzinga • 04/05/21
Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid LeukemiaGlobeNewsWire • 04/05/21
Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual MeetingGlobeNewsWire • 03/11/21
Bio-Path Holdings, Inc (BPTH) CEO Peter Nielsen on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/10/21